FibroGen, Inc., today announced that two abstracts relating to FG-4592, its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) clinical candidate for the treatment of anemia in chronic kidney disease, have been accepted for oral and poster presentations at the American Society of Nephrology (ASN) Kidney Week 2012. The annual meeting will be held October 30 - November 4, 2012, in San Diego, California. Full abstracts can be viewed online at http://www.asn-online.org/education/kidneyweek/archives/.
The schedule and details for the FG-4592 oral and poster presentations at ASN are as follows:
-
FG-4592, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, Corrects Anemia Without Iron Supplementation in Incident Dialysis Patients.
Thursday, November 1, 2012, 4:30 p.m. - 6:30 p.m.
Oral Program # TH-OR096 (Besarab, et al).
-
FG-4592, a Novel Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), Maintains Hemoglobin Levels and Lowers Cholesterol in Hemodialysis (HD) Patients: Phase 2 Comparison with Epoetin Alfa.
Friday, November 2, 2012, 10:00 a.m. - 12:00 p.m.
Poster Board # FR-PO257 (Provenzano, et al).
Gene therapy and glycoside drugs offer new hope for polycystic kidney disease treatment